Lifetime of transplanted kidneys can be prolonged

Lifetime of transplanted kidneys can be prolonged

The drug Belatacept, which the Medical University of Vienna – represented by Ferdinand Mühlbacher, Head of the University Department of Surgery and the immunologist Thomas Wekerle – was greatly involved in the development of, has been approved for almost two years now. Belatacept is a co-stimulation blocker that suppresses the immune response in kidney transplants and has few side effects. "Plus there are indications that the drug can also help significantly prolong the lifetime of the transplanted organ," says Wekerle.

There is no final data available yet on the lifetime of transplanted kidneys and subsequent therapy with Belatacept, however estimates predict a prolongation of several years compared to the current treatment regime based on the conventional immunosuppressants known as calcineurin inhibitors.

The new therapy also has another advantage compared to calcineurin inhibitors: it has no non-specific side effects. For almost 30 years, have been used for the lifelong suppression of adverse reactions of the immune system to . These drugs have been associated with possible adverse side effects such as , disturbances of fat metabolism or diabetes.

At the same time, Belatacept is much easier to administer as a medication: every four weeks, the patient is given an infusion that takes around 30 minutes. With , the patients have to take tablets every day. At the present time, Belatacept treatment is not funded by health insurance funds. The costs for patients treated with this drug at the Vienna General Hospital / MedUni Vienna, however, are paid for by the hospital and/or university. Says Wekerle: "Of course, in an ideal world the costs would be borne by the social security funds."

A vision of the future: bone marrow transplant instead of medication

Current research being carried out by MedUni Vienna scientists, however, is already going one step further. In future, will no longer be required at all, being replaced by a from the donor. This prevents any defence reaction against the "foreign" organ.

This is however still associated with adverse side effects: recipients must first be irradiated and be given synthetic substances (cytostatics) to inhibit cell growth or cell division. This treatment is associated with nausea and a reduction in white and/or red blood cells. "If we are able to reduce this toxicity or eliminate it altogether, it would be revolutionary," says Wekerle. "If we are able to get the foreign bone marrow to graft, the recipient will not recognise the donor organ as foreign. There will be no immune response. Instead, the patient tolerates it." Initial pilot studies have shown that this method promises success.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Doctor behind 'free radical' aging theory dies

13 hours ago

Dr. Denham Harman, a renowned scientist who developed the most widely accepted theory on aging that's now used to study cancer, Alzheimer's disease and other illnesses, has died in Nebraska at age 98.

Mexican boy who had massive tumor recovering

23 hours ago

An 11-year-old Mexican boy who had pieces of a massive tumor removed and who drew international attention after U.S. officials helped him get treatment in the southwestern U.S. state of New Mexico is still recovering after ...

New medical device to make the mines safer

Nov 21, 2014

Dehydration can be a serious health issue for Australia's mining industry, but a new product to be developed with input from Flinders University's Medical Device Partnering Program (MDPP) is set to more effectively ...

US family gets $6.75 million in Botox case

Nov 20, 2014

A New York couple who said Botox treatment of their son's cerebral palsy left him with life-threatening complications and sued its manufacturer won a $6.75 million verdict from a federal jury on Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.